Bleakley Financial Group LLC Grows Holdings in Hologic, Inc. (NASDAQ:HOLX)

Bleakley Financial Group LLC increased its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 6.4% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 4,576 shares of the medical equipment provider’s stock after buying an additional 274 shares during the period. Bleakley Financial Group LLC’s holdings in Hologic were worth $327,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of the stock. Vanguard Group Inc. increased its position in shares of Hologic by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 27,882,301 shares of the medical equipment provider’s stock worth $2,141,919,000 after purchasing an additional 381,608 shares during the last quarter. BlackRock Inc. increased its position in shares of Hologic by 1.2% in the 1st quarter. BlackRock Inc. now owns 23,762,174 shares of the medical equipment provider’s stock worth $1,917,607,000 after purchasing an additional 282,787 shares during the last quarter. State Street Corp increased its position in shares of Hologic by 0.8% in the 1st quarter. State Street Corp now owns 11,426,634 shares of the medical equipment provider’s stock worth $877,794,000 after purchasing an additional 94,561 shares during the last quarter. Macquarie Group Ltd. increased its position in shares of Hologic by 227.2% in the 2nd quarter. Macquarie Group Ltd. now owns 6,284,053 shares of the medical equipment provider’s stock worth $435,485,000 after purchasing an additional 4,363,687 shares during the last quarter. Finally, Victory Capital Management Inc. increased its position in shares of Hologic by 8.9% in the 3rd quarter. Victory Capital Management Inc. now owns 4,838,090 shares of the medical equipment provider’s stock worth $335,763,000 after purchasing an additional 393,371 shares during the last quarter. Institutional investors own 94.73% of the company’s stock.

Hologic Stock Performance

Shares of HOLX opened at $77.33 on Monday. Hologic, Inc. has a 52-week low of $64.02 and a 52-week high of $87.88. The firm has a market capitalization of $18.15 billion, a PE ratio of 36.65, a P/E/G ratio of 2.62 and a beta of 1.00. The firm has a 50-day moving average price of $75.53 and a 200 day moving average price of $72.37. The company has a quick ratio of 3.18, a current ratio of 3.89 and a debt-to-equity ratio of 0.55.

Hologic (NASDAQ:HOLX) last released its quarterly earnings results on Thursday, February 1st. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts’ consensus estimates of $0.95 by $0.03. Hologic had a net margin of 12.98% and a return on equity of 18.91%. The company had revenue of $1.01 billion for the quarter, compared to the consensus estimate of $989.32 million. During the same period in the previous year, the firm earned $1.07 EPS. Hologic’s revenue was down 5.7% on a year-over-year basis. On average, sell-side analysts anticipate that Hologic, Inc. will post 4.02 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction dated Thursday, March 14th. The shares were sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Scott T. Garrett sold 16,441 shares of the business’s stock in a transaction that occurred on Thursday, March 14th. The shares were sold at an average price of $75.50, for a total value of $1,241,295.50. Following the sale, the director now directly owns 48,611 shares in the company, valued at approximately $3,670,130.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the business’s stock in a transaction that occurred on Friday, March 8th. The stock was sold at an average price of $76.21, for a total transaction of $111,647.65. Following the completion of the sale, the director now owns 1,572 shares in the company, valued at $119,802.12. The disclosure for this sale can be found here. In the last three months, insiders have sold 32,846 shares of company stock worth $2,473,443. 1.75% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the stock. Citigroup raised shares of Hologic from a “neutral” rating to a “buy” rating and lifted their price target for the company from $80.00 to $95.00 in a report on Wednesday, April 3rd. StockNews.com lowered shares of Hologic from a “buy” rating to a “hold” rating in a report on Friday, March 8th. UBS Group lifted their price target on shares of Hologic from $78.00 to $79.00 and gave the company a “neutral” rating in a report on Friday, February 2nd. Evercore ISI lifted their price target on shares of Hologic from $76.00 to $78.00 and gave the company an “in-line” rating in a report on Thursday, April 4th. Finally, Raymond James lifted their price target on shares of Hologic from $85.00 to $88.00 and gave the company an “outperform” rating in a report on Friday, February 2nd. Six analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $87.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.